

16 marzo 2015  
MergerMarket

### MEDICINA FUTURA

Medicina Futura, Italian provider of medical diagnostic imaging and laboratory services, is evaluating the offers received by four Italian and European private equity funds, especially British specialized funds, CEO Simone Improta said. Their eventual entry into the capital will be the alternative to listing on AIM Italy, he added. Medicina Futura, active mainly in Campania with the National Health Service, is assisted by the financial advisor Lorenzo Maggiora of Bim-Banca Intermobiliare di Investimenti e Gestioni and by the advisor PwC Corporate Finance. The company has a free capital of EUR 47m: EUR 8m arising from a mini-bonds underwritten by Anthilia Capital Partners SGR through the fund Anthilia Bond Impresa Territorio, EUR 8m from equity of Improta's family and EUR 31m received from the credits of the Italian public administration. With this money Medicina Futura has just bought for EUR 6m Clinica Santa Rita da Cascia in Rome, is buying the largest private hospital in Naples (negotiations are ongoing) and is opening a hospital in Dubai, with the support of the advisor Almutinah owned by the Emir Mohammed bin Rashid Al Maktoum. The cost is between EUR 12m and EUR 15m. With the remaining EUR 9m-EUR 12m the company will buy other medical laboratories in Italy, where it will reach 5 million performance from the current 2.5 million.

Competitors of Medicina Futura are French companies Labco (who last year took over Italian Sdn) and Sinlab. The target market is worth EUR 200m. Medicina Futura has a turnover of EUR 31m in 2013 and expected to reach EUR 47m in 2015 and EUR 70m in 2018. "Our goal is to get quickly to EUR 100m, which will happen very soon if a fund will enter into the capital," Improta said.